Eisai (Tokyo, JP / Nutley, NJ) sponsors 31 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 9 active protocols (3 recruiting now), 18 completed protocols, and 15 all-time original FDA Drugs@FDA NDA and BLA approvals.